GlaxoSmithKline Pharmaceuticals (500660) Q3 24/25 earnings summary

Executive summary

• Achieved significant milestones, including reaffirming long-term commitment at the Bombay Stock Exchange and celebrating 100 years in India with special events and commemorative releases.

• Maintained focus on delivering competitive, above-market performance across all business segments, with continued investment in science, technology, and talent.

• Strong volume growth in general medicines and pediatric vaccines, with leadership in the self-pay private pediatric vaccine market.

• Board approved unaudited standalone and consolidated financial results for Q3 and nine months ended 31 December 2024.

• Mr. Juby Chandy re-appointed as Whole-time Director & CFO for two years from 1 April 2025.

Financial highlights

• Q3 FY25 revenue at ₹946cr, up 18% year-over-year; EBITDA at ₹290cr, up 33% with a margin of 30.7%.

• Q3 FY25 PAT (before exceptional) at ₹229cr, up 37% year-over-year, margin at 24%.

• YTD FY25 (Apr–Dec 2024) revenue at ₹2,757cr, up 10%; EBITDA at ₹839cr, up 30% with a margin of 30.4%.

• Standalone profit after tax for Q3 FY25: ₹22,858 lakhs, up from ₹4,549 lakhs in Q3 FY24; nine months FY25: ₹65,892 lakhs, up from ₹39,161 lakhs in nine months FY24.

• Special interim dividend of ₹12 per share (₹20,329 lakhs) paid in Q3 FY25.

Outlook and guidance

• Sustained focus on top-line and EBITDA growth, leveraging new growth platforms in specialty and oncology, and expanding specialty and pediatric vaccine portfolios.

• Two new oncology assets (for endometrial and ovarian cancer) to launch between Q1 and Q2 of next financial year.

• Continued investment in adult vaccination, digital acceleration, and market presence enhancement.